NCT04410172 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Alaluusua S
Aetiology of Molar-Incisor Hypomineralisation: A systematic review. Eur Arch Paediatr Dent. 2010 Apr;11(2):53-8. Review.
Allazzam SM, Alaki SM, El Meligy OA
Molar incisor hypomineralization, prevalence, and etiology. Int J Dent. 2014;2014:234508. doi: 10.1155/2014/234508. Epub 2014 May 8.
Biondi AM, López Jordi Mdel C, Cortese SG, Alvarez L, Salveraglio I, Ortolani AM
Prevalence of molar-incisor hypomineralization (MIH) in children seeking dental care at the Schools of Dentistry of the University of Buenos Aires (Argentina) and University of la Republica (Uruguay). Acta Odontol Latinoam. 2012;25(2):224-30.
Buchgraber B, Kqiku L, Ebeleseder KA
Molar incisor hypomineralization: proportion and severity in primary public school children in Graz, Austria. Clin Oral Investig. 2018 Mar;22(2):757-762. doi: 10.1007/s00784-017-2150-y. Epub 2017 Jun 19.
Da Costa-Silva CM, Ambrosano GM, Jeremias F, De Souza JF, Mialhe FL
Increase in severity of molar-incisor hypomineralization and its relationship with the colour of enamel opacity: a prospective cohort study. Int J Paediatr Dent. 2011 Sep;21(5):333-41. doi: 10.1111/j.1365-263X.2011.01128.x. Epub 2011 Apr 6.

Prevalence of Molar Incisor Hypomineralization Among a Group Of Egyptian Children Aged From 8 to 12 Years Old in Damietta

Clinical trial NCT04410172 - References